Axonics, Medtronic
Axonics defeats Medtronic lawsuit in spine-stimulation patent trial
Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's patent rights in nerve-stimulation technology.
Axonics did not infringe Medtronic’s patents, jury rules
The Court for the Central District of California has sided with Axonics finding the company did not breach Medtronic’s patents with its r-SNM devices.
Jury rules for Axonics in Medtronic’s long-running neuromodulation patent lawsuit
A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run afoul of three patents held by the company’s main rival, Medt | The case is one of several intellectual property disputes between the medtech giant and Axonics—which is currently waiting to become a subsidiary of Boston Scientific.
Medtronic loses $150M spine patent suit
California-based medical device company Axonics has won a patent infringement trial against Medtronic, according to a Sept. 19 report from Global Data. Medtronic alleged that the company copied three elements of its sacral neuromodulation technology and sought $150 million from the device manufacturer.
Jury sides with Axonics in Medtronic patent dispute
Meanwhile, Boston Scientific is still waiting for antitrust regulators to conclude their review of its proposal to buy Axonics, which was announced in January.
Medtronic Buy Rating Affirmed: Sustained Growth and Strong Pipeline Drive Positive Outlook
Analyst Travis Steed of Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report), retaining the price ...
MassDevice1d
Medtronic has a new VP, GM for TAVR, Congenital Heart
Medtronic (NYSE: MDT) has named Jorie Soskin as its new VP and GM of its TAVR and Congenital Heart businesses.
Zacks.com on MSN2d
Medtronic (MDT) Up 0.7% Since Last Earnings Report: Can It Continue?
Medtronic is part of the Zacks Medical - Products industry. Over the past month, Haemonetics (HAE), a stock from the same industry, has gained 0.3%. The company reported its results for the ...
Medtronic PLC stock outperforms competitors despite losses on the day
Medtronic PLC closed $2.15 below its 52-week high ($91.49), which the company reached on September 4th.
Medtronic (NYSE:MDT) Boosts FY 2025 Guidance Amid Strong Q1 Earnings and Strategic Share Buybacks
Medtronic (NYSE:MDT) is currently navigating a landscape marked by both promising innovations and significant challenges.
Orange County Business Journal3d
Axonics Says Won Patent Case Against Medtronic
The jury found that Axonics does not infringe any of the three patents alleged in the suit, the Irvine-based company said. ...
Medtronic: An Undervalued Stock With Durable Competitive Advantages
Medtronic, a global developer and manufacturer of medical devices for chronic diseases, is now a $111 billion (by market cap) ...